This is out Library. Please click on the article title to view the details.
submitted by: admin on 11/24/2019
Many people ignore prescription drug warning labels according to a study published in the June 2012 issue of the Public Library of Science online journal. There are 15 million drug errors annually in the US, 2 million hospitalizations, and 400,000 deaths.
In a study measuring eye gaze when reading a prescription drug label in people over 50 years of age,...
submitted by: admin on 11/24/2019
As a pharmaceutical industry first, AstraZeneca is stopping payments to doctors for attending international medical conferences. They are making it sound like they are leaders who want to do the right thing...it only took them half a century to figure this out. Do you think this is a move pressured by something other than their benevolence? Their commenton...
submitted by: admin on 09/19/2013
The karma of Big Pharma is revealed in a discussion of the business orientation and lack of ethics. Direct to consumer ads are banned in all countries except the US and New Zealand. Big pharma spends billions every year on DTC ads. Profit is the purpose. More money is spent on advertizing that on research! We are clearly susceptible to DTC ads, they sell prescription...
submitted by: admin on 06/05/2014
According to a study by researchers from the University of Pittsburgh Medical Center that was published in the May 2014 issue of Annals of Internal Medicine, you cannot trust television and magazine ads for US cancer centers. They studied more than 400 ads and report that they mislead patients because they are heavy on emotional appeal and light on the real...
submitted by: admin on 10/09/2013
Avandia remains on the market in the US despite serious health issues that include more than a 50% increase in heart attacks and mortality. All three "glitazones" have safety issues. Rezulin was taken off the market more than a decade ago because of severe liver disease. The third drug, Actos, remains suspicious but up to this point seems to be somewhat...